• Targeting SIRT1-HIF-2α Axis to Decouple NAD+ Dependency in C

  2026-05-19

  This study reveals that chondrosarcomas with poor prognosis rely on elevated NAD+ biosynthesis, governed by the SIRT1-HIF-2α axis. Inhibiting SIRT1 disrupts this metabolic dependency, sensitizing tumors to chemotherapy and offering a mechanistically defined vulnerability for therapeutic targeting.

• (-)-Epigallocatechin Gallate (EGCG): Mechanisms & Research U

  2026-05-19

  (-)-Epigallocatechin gallate (EGCG) is a principal green tea catechin with potent antioxidant, antiangiogenic, antitumor, and antiviral activities. Its multi-modal effects on cellular signaling and pathogen inhibition make EGCG a cornerstone for translational research, as supported by rigorous peer-reviewed evidence.

• Protease Inhibitor Cocktails: Precision Safeguards for Lipid

  2026-05-18

  Explore how the Protease Inhibitor Cocktail (100X H₂O, EDTA Plus) elevates protein stability in advanced lipid droplet research. This in-depth analysis uncovers assay-specific optimization strategies and extracts fresh insight from recent DFCP1-ATGL regulatory discoveries.

• Acetoacetic Acid Sodium Salt: Reliable Solutions for Metabol

  2026-05-18

  This article provides laboratory-validated guidance on deploying Acetoacetic acid sodium salt (SKU A9940) for robust energy metabolism and diabetes research. Drawing on real-world scenarios, we address protocol optimization, data interpretation, and vendor selection, highlighting evidence-backed advantages for cell viability and metabolic pathway studies.

• AM 281: Optimizing CB1 Cannabinoid Receptor Antagonist Assay

  2026-05-17

  AM 281 delivers robust and selective CB1 cannabinoid receptor antagonism, enabling high-fidelity modeling of neuroprotection and memory impairment. Discover how its unique properties streamline experimental workflows, enhance reproducibility, and provide actionable troubleshooting strategies for complex neuropharmacology studies.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi

  2026-05-16

  This study reveals that enhancing GLT-1 expression in mice with traumatic brain injury (TBI) reduces neuronal apoptosis and cognitive dysfunction by suppressing the CB1-CREB signaling axis. These mechanistic insights highlight GLT-1 as a promising target for neuroprotection in TBI and illustrate how CB1 receptor antagonists, such as AM 281, can inform experimental design in cognitive dysfunction research.

• MG-132 (Z-LLL-al): Protocol Innovation in Apoptosis & Cancer

  2026-05-15

  MG-132 (Z-LLL-al) unlocks high-fidelity control in apoptosis assays and cell cycle arrest studies by leveraging potent, selective proteasome inhibition. Explore applied workflows, troubleshooting strategies, and protocol refinements that maximize reproducibility and data clarity for cancer and oxidative stress research.

• GABA-Independent Mechanotransduction of GABAB Receptors Unve

  2026-05-15

  This study reveals that GABAB receptors, traditionally activated by GABA, can also be triggered by mechanical forces through direct integrin interaction, establishing a new paradigm in GPCR mechanotransduction. The findings illuminate how physical cues regulate synaptic and glial function, with implications for neuroscience and cell mechanics research.

• Redefining Live-Cell Golgi Imaging: Strategy for Translation

  2026-05-14

  This thought-leadership article examines how Golgi-Tracker Green, a BODIPY FL-labeled C5-ceramide probe from APExBIO, empowers translational researchers to unravel Golgi apparatus dynamics and sphingolipid metabolism in live cells. By synthesizing mechanistic insight, competitive benchmarking, and protocol best practices, it provides actionable guidance for advancing lipid biology, therapeutic innovation, and experimental reproducibility.

• FITC Goat Anti-Mouse IgG (H+L) Antibody: Protocol and QC Gui

  2026-05-14

  The FITC Goat Anti-Mouse IgG (H+L) Antibody enables reliable fluorescent detection of mouse primary antibodies in immunofluorescence, flow cytometry, and microscopy workflows. This reagent is designed for signal amplification and high specificity in mouse IgG detection. It should not be used for detecting non-mouse IgG or in assays incompatible with FITC-based fluorescence.

• Genetically Encoded NADH/NAD+ Redox Biosensor in E. coli

  2026-05-13

  This article reviews the development of a genetically encoded ratiometric biosensor for NADH/NAD+ in E. coli, which utilizes a redox-sensitive transcriptional regulator to enable high-throughput, noninvasive measurement of intracellular redox state. The study's innovations allow for quantitative mapping of redox metabolism, facilitating both physiological studies and metabolic engineering.

• Applied Workflows with EDTA-Free Protease Inhibitor Cocktail

  2026-05-13

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) from APExBIO delivers robust, EDTA-free protein protection for cell and tissue extracts, enabling high-fidelity downstream analysis—especially in OXPHOS-targeted cancer research. This guide details best-practice workflows, troubleshooting strategies, and key innovations for maximizing protein stability and integrity in advanced experimental settings.

• MG-132 in Cellular Stress Pathways: Precision Tools for Prot

  2026-05-12

  Explore how MG-132 (Z-LLL-al) unlocks new insights into proteostasis regulation, oxidative stress, and apoptosis. This article uniquely bridges state-of-the-art ubiquitin-proteasome research with advanced assay strategies for cancer and cell cycle studies.

• Hydroxytyrosol: Mechanistic Leverage for Translational Impac

  2026-05-12

  This article delivers actionable insights for translational researchers leveraging Hydroxytyrosol—a leading phenolic antioxidant compound—for cardiovascular, inflammation, and oxidative stress models. Synthesizing recent mechanistic evidence and strategic guidance, we explore how APExBIO’s high-purity Hydroxytyrosol (SKU N2302) catalyzes innovation in assay design and translational workflows. With protocol parameters, competitive landscape analysis, and a forward-looking outlook, this resource bridges bench science and real-world application beyond traditional product literature.

• AM 281: Precision CB1 Cannabinoid Receptor Antagonist for Ad

  2026-05-11

  AM 281 empowers researchers to dissect CB1 receptor mechanisms with nanomolar precision, leading to breakthroughs in models of traumatic brain injury and memory impairment. Its high selectivity and protocol versatility make it an indispensable tool in cannabinoid receptor signaling pathway studies and neurodegenerative disease research.

496 records 14/34 page Previous Next First page 上5页 1112131415 下5页 Last page